BCTC (Standard)

[1]Liu T, et al. Anti-tumor activity of the TRPM8 inhibitor BCTC in prostate cancer DU145 cells. Oncol Lett. 2016 Jan;11 (1) :182-188. |[2] Pomonis JD, et al. N- (4-Tertiarybutylphenyl) -4- (3-cholorphyridin-2-yl) tetrahydropyrazine -1 (2H) -carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. in vivo characterization in rat models of inflammatory and neuropathic pain. J Pharmacol Exp Ther. 2003 Jul;306 (1) :387-93.|[3]Kanai Y, et al. Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI rats. Neuropharmacology. 2005 Dec;49 (7) :977-84. |[4] Nie C, et al. Study on chemical modification and analgesic activity of N- (4-tert-butylphenyl) -4- (3-chloropyridin-2-yl) piperazine-1-carboxamide. Eur J Med Chem. 2020 May 15;194:112236. |[5]Tanaka H, et al. Enhanced insulin secretion and sensitization in diabetic mice on chronic treatment with a transient receptor potential vanilloid 1 antagonist. Life Sci. 2011 Mar 14;88 (11-12) :559-63.